Completed PHASE1 INTERVENTIONAL 6-arm NCT02022540

Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD

A Phase I Open-Label, Multi-Center Trial With Randomization to Dose to Evaluate the Safety and Tolerability of Topical Ocular PAN-90806 in Patients With Neovascular Age-Related Macular Degeneration (AMD)

Sponsor: PanOptica, Inc.

Conditions Age-Related Macular Degeneration (AMD)

Interventions Lucentis PAN-90806 Ophthalmic Solution

Updated 6 times since 2017 Last updated: Sep 27, 2016 Started: Feb 28, 2014 Primary completion: Mar 31, 2016 Completion: May 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Age-Related Macular Degeneration (AMD) and is currently completed. PanOptica, Inc. leads this study, which shows 6 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Feb 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

PanOptica, Inc.

Data source: PanOptica, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abilene, United States , Ashland, United States , Austin, United States , Bloomfield, United States , Boston, United States , Charlotte, United States , Colorado Springs, United States , Durham, United States , Harlingen, United States , Madison, United States and 12 more locations